| All | Prophylactic Group | p* | Subgroup | p* | |||
Amiodarone | Placebo | POAF | NO POAF | |||||
Characteristics |
|
|
|
| ||||
N (%) | 228 (100) | 114 (50) | 114 (50) | N/A | 47 (21) | 181 (79) | N/A | |
Age (mean, SD) | 66 (59; 72) | 65 (59; 71) | 66 (59; 74) | 0.405 | 68 (62; 74) | 64 (58; 71) | 0.081 | |
Sex (male, n (%)) | 117 (51) | 57 (50) | 60 (52) | 0.691 | 27 (57) | 90 (50) | 0.345 | |
Current smoker (n (%)) | 86 (38) | 39 (34) | 47 (41) | 0.274 | 17 (36) | 69 (38) | 0.806 | |
Diabetes mellitus (n (%)) | 21 (9) | 14 (12) | 7 (6) | 0.109 | 4 (9) | 17 (9) | 1.000 | |
Hypertension (n (%)) | 75 (33) | 43 (38) | 32 (28) | 0.121 | 22 (47) | 53 (29) | 0.023* | |
Hypercholesterolemia (n (%)) | 34 (15) | 19 (17) | 15 (13) | 0.457 | 8 (17) | 26 (14) | 0.649 | |
COPD (n (%)) | 23 (10) | 13 (11) | 10 (9) | 0.509 | 5 (11) | 18 (10) | 1.000 | |
Previous MI (n (%)) | 4 (2) | ** | ** | 1.000 | ** | ** | 1.000 | |
Preoperative use of β-blockers (n (%)) | 29 (13) | 16 (14) | 13 (11) | 0.551 | 7 (15) | 22 (12) | 0.616 | |
Creatinine (μmol/L) (median, IQR) | 66 (57; 77) | 66 (58; 77) | 65 (54; 76) | 0.180 | 68 (60; 78) | 65 (55; 76) | 0.081 | |
Peri- and Postoperative Characteristics |
|
|
|
| ||||
Postoperative atrial fibrillation (n (%)) | 47 (21) | 10 (9) | 37 (33) | <0.001* | 47 (21) | 181 (79) | N/A | |
Postoperative arrhythmia (n (%)) | ** | ** | ** | N/A | ** | ** | N/A | |
Postoperative blockage (n (%)) | ** | ** | ** | N/A | ** | ** | N/A | |
Reoperation (n (%)) | 8 (4) | 5 (5) | ** | 0.499 | ** | 6 (3) | 0.668 | |
Right side lobectomy (n (%)) | 120 (53) | 59 (52) | 61 (54) | 0.791 | 26 (55) | 94 (52) | 0.679 | |
Bilobectomy (n (%)) | 5 (2) | ** | ** | 1.000 | ** | ** | 0.061 | |
Pneumonectomy (n (%)) | 8 (4) | 4 (4) | 4 (4) | 1.000 | ** | 6 (3) | 0.670 | |
Tumour stage (n (%)) |
|
|
|
|
|
|
| |
| Tumour I | 87 (39) | 39 (35) | 48 (43) | 0.260 | 19 (40) | 68 (38) | 0.802 |
| Tumour II | 99 (44) | 56 (51) | 43 (38) | 0.062 | 23 (49) | 76 (43) | 0.462 |
| Tumour III | 31 (14) | 13 (12) | 18 (16) | 0.361 | ** | 28 (16) | 0.096 |
| Tumour IV | 7 (3) | ** | 4(4) | 1.000 | ** | 5 (3) | 0.639 |
Nodulus stage (n (%)) |
|
|
|
|
|
|
| |
| Nodulus I | 32 (14) | 15 (14) | 17 (15) | 0.743 | 6 (13) | 26 (15) | 0.738 |
| Nodulus II | 36 (16) | 14 (13) | 22 (20) | 0.162 | 7 (15) | 29 (16) | 0.805 |
Metastasis stage (n (%)) |
|
|
|
|
|
|
| |
| Metastasis I | 10 (5) | 5 (5) | 5 (4) | 1.000 | ** | 9 (5) | 0.692 |
| Metastasis II | ** | ** | ** | N/A | ** | ** | N/A |
Tumour size (mm) (median, IQR) | 31 (20; 50) | 32 (20; 50) | 30 (20; 45) | 0.671 | 30 (20; 41) | 32(20; 50) | 0.669 | |
Length of stay in ICU (days) (median, IQR) | 1 (1; 1) | 1 (1; 1) | 1 (1; 1) | 0.774 | 1 (1; 1) | 1 (1; 1) | 0.785 | |
Length of stay in referring department (days) (median, IQR) | 4 (3; 5) | 4 (3; 5) | 4 (3; 5) | 0.699 | 4 (3; 5) | 4 (3; 5) | 0.334 |